New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
10:55 EDTETRMEnteroMedics may have shot for panel backing if FDA benign, TheStreet says
The FDA's review of EnteroMedics' VBLOC implantable medical device for weight loss will likely be publicly available tomorrow morning if the agency "follows historical form," according to TheStreet's Adam Feuerstein. The author believes the company "just might have a decent shot at a positive panel vote" if the review is "relatively benign," but added that if the agency "slams" VBLOC, EnteroMedics will be in "a heap of trouble" at the panel meeting next Tuesday, June 17. Reference Link
News For ETRM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 14, 2015
14:07 EDTETRMEnteroMedics price target raised to $5 from $4 at Craig-Hallum
Subscribe for More Information
10:39 EDTETRMEnteroMedics confirms FDA approval of VBLOC obesity treatment
Subscribe for More Information
10:21 EDTETRMEnteroMedics obesity device approved by FDA
The FDA approved the Maestro Rechargeable System for certain obese adults, the first weight loss treatment device that targets the nerve pathway between the brain and the stomach that controls feelings of hunger and fullness. The Maestro Rechargeable System, the first FDA-approved obesity device since 2007, is approved to treat patients aged 18 and older who have not been able to lose weight with a weight loss program, and who have a body mass index of 35 to 45 with at least one other obesity-related condition, such as type 2 diabetes. The Maestro Rechargeable System is manufactured by EnteroMedics. As part of the approval, the manufacturer must conduct a five year post approval study that will follow at least 100 patients and collect additional safety and effectiveness data including weight loss, adverse events, surgical revisions and explants and changes in obesity-related conditions.
10:17 EDTETRMEnteroMedics trading halted, pending news

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use